Loading
Life sciences · Journal article
Frontiers in Immunology · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
In situ vaccination (ISV) is a local tumor-directed immunotherapy strategy that uses a treated tumor as an endogenous, patient-specific source of tumor antigens and a site of immune activation, with the goal of converting local treatment into systemic and durable antitumor immunity. Depending on the modality, ISV induces immunogenic cell death, other forms of tumor-cell stress or death, or local innate immune activation, thereby increasing antigen availability, promoting type I interferon signaling, and supporting dendritic cell–mediated cross-priming of tumor-reactive T cells capable of mediating both local and systemic antitumor immunity, including regression of untreated lesions. Across immunocompetent preclinical models, ISV can generate durable local tumor control, abscopal responses, and long-term immune memory, particularly when combined with modalities that amplify antigen release or inflammatory signaling. Early clinical studies employing intratumoral innate immune agonists, radiotherapy-based regimens, cytokines, and oncolytic viruses demonstrate clinical feasibility, favorable safety profiles, and emerging evidence of systemic efficacy in selected tumor types. In this review, we discuss the immunologic principles underlying ISV and organize the field according to major triggering modalities, including radiotherapy, ablation, and light-based therapies, selected chemotherapies, innate immune agonists, cytokines, and oncolytic viruses. We further highlight emerging intratumoral delivery platforms, such as lipid nanoparticles, injectable hydrogels, and biodegradable scaffolds, that enable precise spatial and temporal control of immune activation within the tumor microenvironment. Finally, we review the evidence that locally initiated antitumor immunity can extend beyond the treated lesion to control untreated lesions and metastatic disease, and discuss the challenges associated with achieving durable systemic efficacy and preventing recurrence.